Résumé
Prasugrel is a member of the thienopyridine class of oral antiplatelet agents.A single oral administration of prasugrel produced a dose-related inhibition of platelet aggrega-tion in rats that was approximately 10 and 100 fold more potent than that of clopidogrel and ticiopidine, respectively. The antiaggregatory effect of prasugrei was evident at 30 minutes and lasted until 72 hours after dosing, indicating fast onset and long duration of action. Combined administration of prasugrel with aspirin produced substantially greater inhibition of both platelet aggregation and thrombus formation compared with each agent alone. Clinical studies in patients with cardiovascular disease confirmed the potent antiplatelet effect of prasugrel compared with ciopidogrel. Prasugrei is a highly effective antiplatelet and antithrombotic agent and is anticipa-ted to be effective in the treatment of atherothrombotic and other ischemic vascular diseases.